(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 300.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Cytokinetics's revenue in 2024 is $7,530,000.On average, 8 Wall Street analysts forecast CYTK's revenue for 2024 to be $1,585,345,492, with the lowest CYTK revenue forecast at $309,014,130, and the highest CYTK revenue forecast at $5,562,254,340. On average, 9 Wall Street analysts forecast CYTK's revenue for 2025 to be $17,065,717,348, with the lowest CYTK revenue forecast at $5,992,814,028, and the highest CYTK revenue forecast at $40,651,838,849.
In 2026, CYTK is forecast to generate $54,300,374,942 in revenue, with the lowest revenue forecast at $23,073,055,040 and the highest revenue forecast at $72,438,062,308.